Vimarsana
Biggest News Aggregation in the World

Page 6 - Laboratory Abnormalities News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Laboratory Abnormalities. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Laboratory Abnormalities Today - Breaking & Trending Today

New ERLEADA® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) - Vimarsana News

New ERLEADA® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA®...

Aadi Bioscience Announces FDA Approval of its First Product FYARRO™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa) - Vimarsana News

Aadi Bioscience Announces FDA Approval of its First Product FYARRO™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)

Aadi Bioscience Announces FDA Approval of its First Product FYARRO™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa) - read this article along with other careers information, tips and advice on BioSpace

Kedrion Biopharma to commercialize RYPLAZIM® (plasminogen, human-tvmh) in U.S. to address unmet need in patients with ultra-rare condition: Plasminogen Deficiency Type 1 - Vimarsana News

Kedrion Biopharma to commercialize RYPLAZIM® (plasminogen, human-tvmh) in U.S. to address unmet need in patients with ultra-rare condition: Plasminogen Deficiency Type 1

/PRNewswire/ -- Kedrion Biopharma, an international biopharmaceutical company specialized in the manufacture and distribution of plasma-derived therapeutic...

ERLEADA® (apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence Rates - Vimarsana News

ERLEADA® (apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence Rates

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data demonstrating robust prostate-specific antigen (PSA)...

Liminal BioSciences Announces FDA Approval for its Biologics License Application for Ryplazim® (plasminogen, human-tvmh) - Vimarsana News

Liminal BioSciences Announces FDA Approval for its Biologics License Application for Ryplazim® (plasminogen, human-tvmh)

/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced today that the U.S. Food & Drug Administration (FDA)...